Search
Obecabtagene autoleucel
go.drugbank.com/drugs/DB17362ApprovedInvestigationalObecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19. … [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Synonyms: A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING O, AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODINGReserpine
go.drugbank.com/drugs/DB00206ApprovedWithdrawnThe FDA withdrew its approval for the use of all oral dosage form drug products containing more than 1 mg of reserpine.[L43942] … It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
Oxymorphone
go.drugbank.com/drugs/DB01192ApprovedVet approvedOn June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.
Perboric acid
go.drugbank.com/drugs/DB13235ApprovedPerboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate or tetrahydrate. … [L1113] By the FDA, sodium perborate is approved as an ointment for the protection of poison ivy dermatitis.[L2764]
Ferrous sulfate anhydrous
go.drugbank.com/drugs/DB13257ApprovedInvestigational[A190804] This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells. … Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age.
Mixtures: Phytofortis + Calcium A-D, Hormodausse Plus Calc Et D TabVanzacaftor
go.drugbank.com/drugs/DB18373ApprovedInvestigational], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations. … [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor
Enmetazobactam
go.drugbank.com/drugs/DB18716ApprovedInvestigationalEnmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. … [A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.
Aldesleukin
go.drugbank.com/drugs/DB00041ApprovedInvestigationalAldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. … Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2.
Albinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalAlbumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. … Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C.
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigationalMavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. … by a reduced number of mature neutrophils and lymphocytes.